Quintiles Enters Strategic Five-Year Agreement With Biogen Idec
By Ed Miseta, Chief Editor, Clinical Leader
Biopharmaceutical development and commercial outsourcing firm Quintiles has announced it is entering into a strategic five-year deal with Biogen Idec, a developer of treatments for neurodegenerative diseases, hemophilia, and autoimmune disorders. According to a release by the companies, the agreement is intended to leverage the experience and expertise of both companies to optimize the clinical development process at Biogen Idec.
Per the agreement, a dedicated team from Quintiles will work with Biogen Idec on the design, planning, and execution of Phase II-IV studies, as well as some select Phase I studies. The collaboration is already underway with new projects being initiated via the collaboration. Several Biogen Idec ongoing studies are transitioning to Quintiles as well.
Company comments:
“Our partnership with Biogen Idec exemplifies the ongoing evolution of drug development collaboration and reinforces the increasingly important role that biopharmaceutical service providers such as Quintiles have in these efforts,” said Tom Pike, chief executive officer, Quintiles. “We are extremely excited about this agreement and the increased interest we are seeing for these types of innovative development deals. We believe Quintiles is uniquely positioned to help our customers improve their probability of success through these collaborations, and we look forward to working closely with Biogen Idec.”
“As we have continued to build our research and development organization, it was important for us to identify a strong clinical development partner to complement our focus on developing innovative therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases,” said Alfred Sandrock, M.D., Ph.D., group senior vice president, Development Sciences and chief medical officer, Biogen Idec. “What attracted us to Quintiles was their depth and breadth of experience, which we believe will enhance the design, planning and operational elements of our clinical programs."